$14.55
1.11% yesterday
Nasdaq, Sep 08, 10:15 pm CET
ISIN
US5907171046
Symbol
MESO

Mesoblast Limited Sponsored ADR Stock News

Neutral
GlobeNewsWire
5 days ago
NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 ...
Neutral
Seeking Alpha
11 days ago
Mesoblast Limited (NASDAQ:MESO ) Q4 2025 Earnings Conference Call August 28, 2025 6:30 PM ET Company Participants Andrew Chaponnel - Interim Chief Finance Officer Marcelo Santoro - Chief Commercial Officer Silviu Itescu - Founder, CEO, MD, Chairman of Scientific Advisory Board & Executive Director Conference Call Participants Edward Andrew Tenthoff - Piper Sandler & Co., Research Division Elyse...
Neutral
GlobeNewsWire
12 days ago
Financial Results and Operational Update for the Full Year Ended June 30, 2025 Financial Results and Operational Update for the Full Year Ended June 30, 2025
Neutral
GlobeNewsWire
about 2 months ago
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first quarter post product launch. Ryoncil® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became c...
Neutral
GlobeNewsWire
2 months ago
NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items required for filing a Biologics License Application (BLA) for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic heart failure with...
Neutral
GlobeNewsWire
3 months ago
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) regarding both accelerated approval pathway for Revascor® (rexlemestrocel-L) in the treatment of patients with ischemic chronic heart failure wi...
Neutral
GlobeNewsWire
4 months ago
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received seven years of orphan-drug exclusive approval from U.S. Food and Drug Administration (FDA) for Ryoncil® (remestemcel-L) for treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatr...
Positive
Seeking Alpha
4 months ago
MESO's Off-the-shelf MSC/MPC platform treats severe inflammatory diseases without donor–recipient matching. This alleviates the typical need for immunosuppression. The FDA recently approved Ryoncil, which achieved as much as 70% response in pediatric SR-aGVHD patients. And it has adult SR-aGVHD and Crohn's Phase 3 trials underway. MESO's Revascor is also in trials for chronic low back pain and ...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today